Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALG 097558

Next Previous
Drug Profile

ALG 097558

Alternative Names: ALG-097558; Coronavirus therapeutic - Aligos Therapeutics/Centre for Drug Design and Discovery/Rega Institute for Medical Research

Latest Information Update: 03 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aligos Therapeutics; Centre for Drug Design and Discovery; Rega Institute for Medical Research
  • Developer Aligos Therapeutics; University of Liverpool
  • Class Antivirals; Small molecules
  • Mechanism of Action Coronavirus 3C-like proteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II COVID 2019 infections

Most Recent Events

  • 13 May 2025 Aligos Therapeutics and National Institute of Allergy and Infectious Diseases initiate enrollment in a phase I trial in COVID-2019 infections (In volunteers) in USA (PO) (NCT06945276)
  • 25 Apr 2025 National Institute of Allergy and Infectious Diseases plans phase I trial in COVID-2019 infections (PO) (NCT06945276)
  • 09 Mar 2025 Pharmacodynamics data from a preclinical trial in COVID-2019 infections presented at the 32nd Conference on Retroviruses and Opportunistic Infections 2025 (CROI-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top